Refine by
Patient Assessment Articles & Analysis
63 news found
In addition, cryolipolysis treatment can also lead to complications if patients are not adequately examined and assessed prior to treatment. 3. ...
Baseline Disease Characteristics of Patients Who Maintained 12- and 16-Week Aflibercept 8 mg Dosing Versus Patients with Shortened Treatment Intervals Through Week 48 in the Phase 2/3 PHOTON Trial Podium presentation April 25, 2023; 12.15-12.30 EST The analysis of the PHOTON trial evaluates the treatment effects of aflibercept 8 mg versus 2 mg at Week 48 ...
ByBayer AG
“We are all united by our ultimate mission of bringing world-class care and treatment to patients around the world, and we strive to foster a culture that encourages collaboration and visionary thinking to help us drive our innovation ...
It is estimated that around 40 percent of eligible patients are either not treated with direct oral anticoagulants or undertreated as these patients assess the bleeding risk to be higher than their need for thrombosis prevention. ...
ByBayer AG
In fact, the disease is responsible for “two million broken bones and $19 billion in related costs every year”, while by the year 2025, “experts predict that osteoporosis will be responsible for approximately three million fractures and $25.3 billion in costs annually.” Sadly, most patients are not aware of having the condition before suffering from a ...
“As we continue to expand our clinical research program, we’re looking forward to improving our trial recruitment efforts with more accurate patient screening and identification, and ultimately, increasing patient access to trials and ...
This award demonstrates the tremendous effort our team puts in everyday to develop technology that will benefit patients everywhere.” Iterative Health was selected from a pool of over 13,000 private companies and was chosen based on its R&D activity, market potential, business relationships, investor profile, competitive landscape, team strength, and tech novelty. ...
Methods for collecting patient information involve questionnaire-based assessments with branching logic and scoring, computer-assisted telephone interviewing (CATI), interactive voice response systems (IVRS), and screen-based systems. ePROM may be administered at a clinic or remotely in an unsupervised setting, such as the home or workplace. ...
AI Recruitment (AI-R) addresses clinical trial recruitment pain points for pharmaceutical companies and clinical research teams working to surface eligible patients for inflammatory bowel disease (IBD) clinical trials. Recruiting qualified patients is one of the most significant and expensive challenges of clinical trials, but AI-R helps determine if ...
In times of pandemic, cardiac rehabilitation centres search for solutions which allow them to continue remote rehabilitation, while making it possible to maintain constant contact with the patient. This solution must provide possibility to assess the patient's condition before training, set training parameters adjusted to individual needs and ...
Bodyport, a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. The scales can detect these signals through the feet when a patient steps onto the device. ...
“We continue to be motivated by the data seen in this Phase 2a study of VBI-1901 as we endeavor to provide new treatment options to patients with very few available to them,” said David E. Anderson, Ph.D., VBI’s Chief Scientific Officer. ...
“We are excited to work alongside Interpace Diagnostics and Twist Bioscience in providing better solutions in cancer diagnostics for patients and patients’ families,” said Alejandro Tocigl, Miroculus CEO. ...
Because of the clinic’s proximity to Fluidda, De Backer has been able to regularly use Fluidda’s FRI technology to assess patients. Prof De Backer: “We try to phenotype the patients as much as we ...
ByFluidda
The Barostim System now includes instructions to allow for safe MRI scans of the head and lower extremities, meaning heart failure patients implanted with Barostim have more diagnostic options. All Barostim System patients, including those already receiving Barostim therapy, can safely receive an MRI at 1.5T when conditions of use are met. "This is a significant ...
ByCVRx
With no drug-limiting toxicities observed at lower doses, Genenta has now dosed the first patient in a new cohort (cohort 6) with 3.0 x 106 Temferon cells per kilogram, 50% higher than the next highest prior level. ...
Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023 Phase 3 TRANQUILITY III study underway with patient enrollment initiating in H2 2022 BioXcel Therapeutics, Inc. ...
Thirty-five patients completed treatment with 60 gray of intensity-modulated radiation therapy (IMRT) plus chemotherapy over six weeks. Of these 35 patients, 29 received at least five weeks of 90 mg of avasopasem on the days they underwent IMRT. These 29 patients were evaluated as the pre-specified per protocol population. ...
Based on the results of these studies, we have been using FFRangio as a standalone tool for physiologic assessment in patients undergoing coronary angiography, and it has become the standard of care in our cath lab replacing wire-based FFR. ...
“Our team started using the PiCSO therapy for anterior STEMI patients in 2021. We are delighted to explore new indications and now start using PiCSO for inferior STEMI patients in the context of the PiCSO-AMI-V study,” says Prof. ...